Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 4,55 € (+373,96 %). La médiane est de 4,55 € (+373,96 %).
| Acheter |
9 |
| Conserver |
5 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Codexis unveils enzymatic ECO‑Synthesis for siRNA and targets kilogram‑scale production by 2027
At the Cantor Fitzgerald conference, Codexis presented its ECO‑Synthesis platform for enzymatic siRNA manufacture as a capital‑ and solvent‑sparing alternative to solid‑phase organosynthesis, citing roughly 70% higher capital efficiency. Its innovation lab routinely produces 100 grams, plans 500 grams by late 2024/early 2025, and aims for kilogram‑scale production by the end of 2027. The company highlighted technical advances such as stereochemical control and initiation from a single nucleotide, and said it is in ongoing dialogue with the FDA on product specifications and comparability. Codexis is targeting CDMO partnerships, collaborations with pharmaceutical companies and licensing to address siRNA industry scaling bottlenecks. » Plus sur de.investing.com
Codexis beats Q1 2026 forecasts — revenue more than doubles
Codexis reported Q1 2026 EPS of -0.10 (expectation -0.16) and revenue of $15.2 million versus $14.79 million expected. Revenue rose 102.7% year over year, mainly due to a technology transfer agreement with Merck; product gross margin improved to 71%. Operating expenses were reduced, net loss narrowed significantly, and cash reserves are expected to fund the business through the end of 2027. For Q2 the company expects around $16.5 million in revenue; the stock rose about 1.5% in after-hours trading. » Plus sur de.investing.com
Codexis beats Q4 2025 expectations thanks to Merck deal and strong revenue growth
Codexis reported Q4 2025 EPS of 0.11 USD (expectation -0.04 USD) and revenue of 38.92 million USD, up 81% year-on-year. A technology transfer agreement with Merck contributed 37.8 million USD to quarterly revenue and raised the gross margin to 64%. For the full year the company still records a net loss of 44 million USD despite the quarter’s results, expects negative EPS for 2026, and is focused on expanding the ECO-Synthesis platform and a GMP production facility by the end of 2027. » Plus sur de.investing.com
Codexis signs manufacturing deal for 50 g siRNA to support preclinical development
Codexis agreed with a pharmaceutical company to manufacture 50 grams of siRNA using its ECO Synthesis platform to support a preclinical candidate for a cardiovascular indication. The order is intended to demonstrate that the platform can deliver quantities beyond early research volumes and lays the groundwork for potential scale‑up if the program advances. Financial terms and the partner’s name were not disclosed; the stock trades near its 52‑week low, but analysts have recently raised estimates and price targets. » Plus sur de.investing.com
Codexis aligns strategy toward RNA therapeutics and plans GMP production
Codexis announced at the TD Cowen Healthcare Conference a strategic realignment toward RNA therapeutics, leveraging its ECO synthesis platform to scale and improve efficiency. A new GMP production facility, with investments of $20–25 million, is planned to be operational by 2027; scaling production to kilogram levels is planned by the end of 2026. The company sees an addressable market of about $2 billion for RNA medicines by 2030, has 11 drug candidates in Phase 3, and has signed a supply agreement with Merck to strengthen its supply chain. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 17,01 M | 132,02 % |
| Bénéfice brut | 13,46 M | 157,46 % |
| Bénéfice net | -7,18 M | 57,07 % |
| EBITDA | -4,98 M | 63,96 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 106,8 M € |
Nombre d'actions | 109,6 M |
Plus haut/bas sur 52 semaines | 2,71 € - 0,82 € |
| Dividendes | Non |
Bêta | 2,39 |
Ratio P/E | -5,46 |
Ratio PEG | -0,03 |
Ratio P/B | 2,24 |
Ratio P/S | 1,33 |
Profil de l'entreprise
Codexis, Inc. découvre, développe et commercialise des enzymes et d'autres protéines. Elle propose des produits et services de biocatalyse ; des produits chimiques intermédiaires destinés à être utilisés pour des transformations chimiques ultérieures ; ainsi que des panels et kits de biocatalyseurs Codex permettant aux clients de réaliser des criblages chimiques. La société fournit également des services de criblage de biocatalyseurs et d'ingénierie des protéines. Elle propose en outre la plateforme technologique d'ingénierie des protéines CodeEvolver, qui contribue au développement et à la livraison de biocatalyseurs capables de réaliser des transformations chimiques et d'améliorer l'efficacité et la productivité des procédés de fabrication. La plateforme de la société sert également à découvrir de nouveaux candidats-médicaments biothérapeutiques destinés à traiter des maladies humaines ciblées, ainsi que des enzymes de biologie moléculaire et de diagnostic in vitro. Elle commercialise ses produits auprès des fabricants pharmaceutiques via ses forces de vente directes et ses équipes de développement commercial aux États-Unis et en Europe. La société a été constituée en 2002 et son siège social est situé à Redwood City, en Californie.
| Nom | Codexis |
| PDG | Alison Moore |
| Siège social | Redwood City,
ca États-Unis |
| Site web | |
| Secteur | Énergie |
| Industrie | Pétrole, gaz et combustibles consommables |
| Introduction en bourse | 22/04/2010 |
| Employés | 146 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | CDXS |
London Stock Exchange | 0I0X.L |
Frankfurt | 4QK.F |
Düsseldorf | 4QK.DU |
London | 0I0X.L |
SIX | 4QK.SW |
München | 4QK.MU |